GENFAR
LIVE

Serial Number

98504518

Owner

Genfar S.A.

Attorney

Stacy J. Grossman

Filing Date

Apr 17, 2024

Add to watchlist:

No watchlists yet
View on USPTO

GENFAR Trademark

Serial Number: 98504518 • Registration: 8140449

GENFAR is a trademark filed by Genfar S.A. on April 17, 2024. The trademark is classified under Class 5 (Pharmaceuticals), Class 35 (Advertising & Business). The application is currently registered and active.

Owner Contact Info

Genfar S.A.

Zona Industrial Montevideo
Bogotá D.C. 111611 , CO

Entity Type: 99

Trademark Details

Filing Date

April 17, 2024

Registration Date

February 17, 2026

Published for Opposition

December 30, 2025

Goods & Services

Business representative services in the nature of independent sales representatives, and import-export agencies, all in the fields of pharmaceutical products, pharmaceutical preparations, medicines for human and veterinary health, antibiotics, dermatological, ophthalmological, otological and homeopathic medicines, medicines for animal health and other medicines for the defense and protection of human and veterinary health

Pharmaceutical products of chemical synthesis and biologics for human use for the prevention and treatment of acute and chronic diseases for different age groups relating to the nervous system, cardiovascular system, respiratory system, endocrine system, digestive system, genitourinary system, musculoskeletal system, sensory systems, hematopoietic system, and immune system; Pharmaceutical products in the form of prescription and non-prescription drugs, namely, pills, tablets, capsules, granulates, sachets, drops, syrups, injectables, inhalers, patches, creams, gels, suppositories, ovules, implants, and any pharmaceutical form that allows adequate administration of the drug, all for the prevention and treatment of chronic diseases for different age groups relating to the nervous system, cardiovascular system, respiratory system, endocrine system, digestive system, genitourinary system, musculoskeletal system, sensory systems, hematopoietic system, and immune system; Pharmaceutical preparations for the treatment and prevention of acute and chronic diseases of the nervous, cardiovascular, respiratory, endocrine, digestive, genitourinary, musculoskeletal, sensory, hematopoietic, and immune systems; drugs in the nature of pharmaceutical preparations for the treatment of infections caused by bacteria, viruses, fungi, parasites, and other germs; Chemical and biological preparations for medical and pharmaceutical uses for the treatment and prevention of acute and chronic diseases relating to infectious diseases, neurological diseases, psychiatric conditions, endocrinological diseases, digestive diseases, cardiovascular diseases, renal diseases, respiratory diseases, sense organ diseases, musculoskeletal diseases, and male and female reproductive organ diseases relating to contraceptives, immunological diseases, allergic conditions, inflammatory diseases, skin and adnexa dermatological diseases, oncological conditions, and hematopoietic diseases; Vaccines; Baby food; Medical plasters; Dressing materials, namely, medical dressings; Disinfectants; Vitamins; Vitamin preparations; Food supplements for medicinal purposes; Mineral food supplements for medicinal purposes; Nutritional supplements; Herbal preparations for medicinal purposes; Food supplements containing protein, carbohydrates, fat, fiber and micronutrients in the form of vitamins, mineral supplements, amino acid preparations for medicinal purposes and fatty acids for medicinal purposes

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 17, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Feb 17, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Dec 30, 2025 NPUB
PUBLISHED FOR OPPOSITION
Dec 30, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 24, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 3, 2025 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 3, 2025 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 3, 2025 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 3, 2025 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 3, 2025 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 2, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 2, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 2, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 26, 2025 GNRN
NON-FINAL ACTION E-MAILED
Nov 26, 2025 GNRT
NON-FINAL ACTION WRITTEN
Nov 26, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 25, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 25, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Nov 25, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Sep 9, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Sep 9, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Sep 9, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Jul 29, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jan 28, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jan 28, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jan 28, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 28, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 28, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 28, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 15, 2025 GNRN
NON-FINAL ACTION E-MAILED
Jan 15, 2025 GNRT
NON-FINAL ACTION WRITTEN
Jan 15, 2025 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 14, 2025 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 14, 2025 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 30, 2024 GNRN
NON-FINAL ACTION E-MAILED
Oct 30, 2024 GNRT
NON-FINAL ACTION WRITTEN
Oct 30, 2024 CNRT
ASSIGNED TO EXAMINER
Oct 30, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 2, 2024 NWOS
NEW APPLICATION ENTERED
Apr 17, 2024 NWAP